RxDoctor Payments Data

Robert Dean, DO

Family Medicine · Collinsville, OKNPI 1053427815

Payments from drug & device makers

$13,240in general payments, 2019–2025

Across 807 payments — averaging $16.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Pfizer$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • GSK$991
  • Amgen$869
  • plus $6K from 39 others

What the payments were for

  • Food & beverage$13,15199%
  • Education$891%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,240 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$75,257
Medicare patients
250
Services billed
1,560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban138$130,320
JardianceEmpagliflozin59$58,060
FarxigaDapagliflozin Propanediol50$44,353
TrulicityDulaglutide45$41,476
MounjaroTirzepatide45$41,321
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$30,241
XareltoRivaroxaban29$27,479
OzempicSemaglutide28$24,090
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$22,025
Synjardy XrEmpagliflozin/Metformin Hcl16$21,380
JanuviaSitagliptin Phosphate11$12,869
Rosuvastatin Calcium336$12,530
Xigduo XrDapaglifloz Propaned/Metformin11$9,737
Breo ElliptaFluticasone/Vilanterol14$8,985
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$8,745

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,292$130,320138 claims
Boehringer IngelheimJardiance, Synjardy Xr, Combivent Respimat$474$85,38088 claims
Lilly USA, LLCTrulicity, Mounjaro$1,030$82,79790 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,745$66,37886 claims
GSKTrelegy Ellipta, Breo Ellipta$991$39,22663 claims
Johnson & JohnsonXarelto$552$27,47929 claims
Novo NordiskOzempic$1,273$24,09028 claims
MerckJanuvia$353$12,86911 claims
Kowa Pharmaceuticals America, Inc.Livalo$342$4,14211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Collinsville

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →